Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).
Saranya Chumsri(Jacksonville College), E. Aubrey Thompson(Mayo Clinic in Florida), Susanna Lauttia(University of Helsinki), Henrik Lindman(Uppsala University), Torsten O. Nielsen(University of British Columbia), Jennifer M. Kachergus(Norwegian University of Science and Technology), Karama Asleh(University of British Columbia), Heather Ann Brauer(Gates Foundation), Heikki Joensuu(Orion Corporation (Finland)), Douglas Hinerfeld
Cited by 1
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k